about
Spondyloarthritis: Matrix Metalloproteinasesas Biomarkers of Pathogenesis and Response to Tumor Necrosis Factor (TNF) Inhibitors.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.Serum HMGB1 Serves as a Novel Laboratory Indicator Reflecting Disease Activity and Treatment Response in Ankylosing Spondylitis Patients.Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.Mechanism of New Bone Formation in Axial Spondyloarthritis.Developments with experimental and investigational drugs for axial spondyloarthritis.The Paradox of Bone Formation and Bone Loss in Ankylosing Spondylitis: Evolving New Concepts of Bone Formation and Future Trends in Management.New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents.Pain in ankylosing spondylitis: a neuro-immune collaboration.Management of patients with inflammatory bowel disease and spondyloarthritis.Gene Expression Analysis before and after Treatment with Adalimumab in Patients with Ankylosing Spondylitis Identifies Molecular Pathways Associated with Response to Therapy.Interleukin-17A-promoted MSC2 polarization related with new bone formation of ankylosing spondylitis.Hematopoietic and mesenchymal stem cells: a promising new therapy for spondyloarthritis?What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?Relationship between diet and ankylosing spondylitis: A systematic review.IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis.Comorbid TNF-mediated heart valve disease and chronic polyarthritis share common mesenchymal cell-mediated aetiopathogenesis.
P2860
Q33624763-7AE5F888-43A2-4A3E-ADA1-6EB194E61284Q33881234-FA53D1FB-7B73-4605-A6A3-1DFFDA081C0EQ37348534-437DFF7C-938C-4BF2-B23C-0AB0844EC7EDQ37442813-47A4EC2D-3C7B-42D8-91E7-0781F7E9B083Q38655991-DB918DCB-6271-4776-B393-C5F250B176AAQ38676714-D31178B2-DE8E-49B1-8E5B-DF5FA078D3A6Q38737389-E4A8482D-81EE-4318-934C-37547A6F44E8Q38768900-DD029288-EC38-40A1-8602-44CC743C8E63Q39374230-29E88BCE-E013-4BFD-98ED-B9589F98396AQ40054186-15A285B7-2566-4116-91BF-26B2A7B287F2Q42081086-64A94C80-3B4E-4646-94DF-648C69E3FEE7Q47123994-BA5BD88F-8C9E-483B-A095-9A298F1EDD43Q50025503-4F0F33D2-0F3E-4B23-95C5-F36CF3834BAFQ50081141-B036DF4D-CEBE-4F11-A7EC-849F830B607DQ53279948-439A06FF-056F-44BF-9B42-D035B4FF1673Q54976780-A1D00D16-665C-480B-852B-5159B8F41E97Q55497929-429FEB16-1458-4167-A646-4FF64950CE7E
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
New evidence on the management of spondyloarthritis.
@en
type
label
New evidence on the management of spondyloarthritis.
@en
prefLabel
New evidence on the management of spondyloarthritis.
@en
P356
P1476
New evidence on the management of spondyloarthritis
@en
P2093
Joachim Sieper
P2888
P304
P356
10.1038/NRRHEUM.2016.42
P407
P577
2016-04-07T00:00:00Z
P6179
1032752398